High throughput screening News and Research

RSS

High-throughput screening (HTS) allows scientists to test thousands of samples at once. These samples can be of a wide variety, and include, but are not limited to, amino acids, chemical compounds or cells.

Methodist Hospital will soon have new brain and pituitary tumor treatment center

Brain and pituitary tumor patients will soon have access to a state-of-the-art facility at The Methodist Hospital, a result of a $10 million dollar commitment from a Houston oil executive.

24 Apr 2013

TSRI scientists identify new drugs for human prion disease

Human diseases caused by misfolded proteins known as prions are some of most rare yet terrifying on the planet—incurable with disturbing symptoms that include dementia, personality shifts, hallucinations and coordination problems.

4 Apr 2013

Sanford-Burnham selects organizations to participate in Florida Translational Research Program

Sanford-Burnham Medical Research Institute at Lake Nona announced the selection of the first five research organizations that will participate in the Florida Translational Research Program to advance drug discovery in the state.

3 Apr 2013

Chromatrap chromatin immunoprecipitation (ChIP) assay range added to Porvair Sciences’ portfolio of products for epigenetics

Porvair Sciences has announced the addition of the novel Chromatrap chromatin immunoprecipitation (ChIP) assay range to its portfolio of products for epigenetics.

From Chromatrap® - Porvair Sciences Ltd 28 Mar 2013

Calibr, JDRF partner to research on promising type 1 diabetes therapeutic targets

The California Institute for Biomedical Research and JDRF announced a partnership today to apply Calibr's drug discovery expertise to type 1 diabetes research projects in collaboration with academic investigators from JDRF's network.

25 Mar 2013

Scientists identify a new way to develop potential drugs for TB

Scientists have developed a way to pinpoint promising drugs to fight tuberculosis (TB) and other diseases without setting foot in the laboratory.

24 Mar 2013

UNM scientists identify chemical compound that appears to control cell metastases

It's the spread of the original cancer tumor that kills most people. That's why cancer researchers vigorously search for drugs that can prevent metastases, the spread of cancer. The research team co-led by Angela Wandinger-Ness, PhD, and Larry Sklar, PhD, at the University of New Mexico Cancer Center has found a chemical compound that appears to control cell migration and adhesion, two important characteristics of metastatic cancer cells.

14 Mar 2013

Scripps Research, Takeda Pharmaceutical to search for new drug targets for different diseases

The Scripps Research Institute and the Takeda Pharmaceutical Company have announced plans to expand their recent research collaboration to search for new drug targets for a variety of diseases.

14 Mar 2013

Sanford-Burnham, Mayo Clinic partner to expand and speed development of new drugs

To expand and speed the development of new drugs for its patients, Mayo Clinic has entered a formal collaboration with Sanford-Burnham Medical Research Institute. Under the agreement, Mayo's discoveries of potential drug targets will be the basis for the development of new drug screening platforms. This will allow future work that focuses on high-throughput screening and medicinal chemistry at Sanford-Burnham facilities.

12 Mar 2013

Two renowned SCCP scientists earn national recognition from Society of Toxicology

Two renowned scientists at the South Carolina College of Pharmacy (SCCP) have garnered national recognition from the Society of Toxicology (SoT), which named them recipients of two of its individual annual awards. It is the first time these awards have gone to individuals from the same College.

27 Feb 2013

GSK, Vanderbilt partner to develop and commercialize new therapies for severe obesity

Vanderbilt University announced today that it has signed a collaboration agreement with GlaxoSmithKline (GSK) for the discovery, development and commercialization of novel therapies for severe obesity.

13 Feb 2013

Combined genomic and proteomic plasma analysis can identify molecular disease mechanisms

For the first time, scientists have combined genomic and proteomic analysis of blood plasma to enhance identification of genetically regulated protein traits. This could be applied to any large association study of civilization diseases where blood plasma has been collected, vastly improving a clinician's ability to identify disease susceptibility in individuals and populations.

11 Feb 2013

Innovative drug discovery in Europe supported by Bayer

Bayer HealthCare initiated and will coordinate a newly founded pan-European consortium, named European Lead Factory, which has been launched to enhance early drug discovery addressing the need for innovative drugs. The new five-year project will create an exceptional small molecule library collection allowing drug discovery on innovative and promising targets from pharma companies and academia.

7 Feb 2013

Finding medical applications for unused inventions: an interview with Gabriel Mecklenburg, Co-Founder of Marblar

Marblar is gamifying the process of technology transfer. We post technology on our platform in the form of a challenge, and the Marblar community then competes to uncover new problems these technologies could solve – thereby discovering new market applications for these technologies.

31 Jan 2013

TSRI scientists to identify, test and develop drug candidates for several neurodegenerative disorders

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded approximately $1.2 million from the U.S. National Institute of General Medical Sciences of the National Institutes of Health to identify, test and develop a series of drug candidates for a number of diseases, including rheumatoid arthritis, heart disease and several neurodegenerative disorders.

28 Jan 2013

Pairing statins with cyclin-dependent kinase inhibitors might effectively treat melanomas

A novel approach to identifying potential anticancer drug combinations revealed that pairing cholesterol-reducing drugs called statins with cyclin-dependent kinase inhibitors might provide an effective approach to treating intractable melanomas driven by mutations in the NRAS and KRAS gene.

14 Dec 2012

Bicycle Therapeutics secures £3.75 million equity financing for drug discovery

Bicycle Therapeutics, a next generation biotherapeutics company co-founded by Sir Gregory Winter and Professor Christian Heinis, today announced that it had secured a tranched equity financing of £3.75 million to invest in selection of drug candidates using its bicyclic peptide technology platform.

10 Dec 2012

Scientists hope to unravel mystery of how Borrelia burgdorferi causes Lyme disease

Investigators at The University of Texas Health Science Center at Houston (UTHealth) have accelerated the search for the bacterial genes that make the Lyme disease bacterium so invasive and persistent. The discovery could advance the diagnosis and treatment of this disease, which affects an estimated 30,000 Americans each year.

29 Oct 2012

Scientists create new compounds that could slow progression of Parkinson's

In an early-stage breakthrough, a team of Northwestern University scientists has developed a new family of compounds that could slow the progression of Parkinson's disease.

25 Oct 2012

TSRI scientists to study structural rules that govern nuclear receptors

A consortium of scientists from both campuses of The Scripps Research Institute (TSRI) has been awarded $2.7 million from the National Institute of General Medical Sciences of the National Institutes of Health to study the structural rules that govern a large superfamily of proteins that help regulate critical functions such as reproduction, development and metabolism.

24 Oct 2012